The number of tuberculosis (TB) patients in the Netherlands decreased considerably in 2017. From 887 patients in 2016 to 787 in 2017.

“RIVM is committed to being innovative, and becoming a key player in citizen science is fully in line with that goal,” says Danielle Timmermans, Chief Science Officer for Risk Communication at RIVM

On 7 November 2018, Raymond Cointe, Director-General of INERIS and Hans Brug, Director-General of RIVM, signed a Framework Agreement. RIVM has been working with the French National Institute f

On 17 and 18 October 2018, RIVM visited the German Environment Agency Umwelt Bundesamt (UBA).

RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.

From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.

RIVM is involved in the Horizon2020 project INHERIT. The first article of the INHERIT project has been published, lead-authored by RIVM.

RIVM’s Collaborating Centre for Risk Assessment of Pathogens in Food and Water was invited to WHO’s side event during the 41st Codex Alimentarius Commission on July 4th 2018.

How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?

The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.